Welcome to our dedicated page for 111 American Depositary Shares news (Ticker: YI), a resource for investors and traders seeking the latest updates and insights on 111 American Depositary Shares stock.
111, Inc. (NASDAQ: YI) operates an integrated online and offline platform in the healthcare market in China. The company operates through two segments: B2B and B2C. 111, Inc. sells medical and wellness products through online retail, wholesale and retail pharmacies, and offline retail pharmacies. The company also provides value-added services like online consultation and e-prescription services.
The company's product portfolio includes:
- Prescription and OTC Drugs: Western and traditional Chinese medicinal drugs.
- Nutritional Supplements: Vitamins and dietary products.
- Contact Lenses: A variety of contact lenses.
- Medical Supplies and Devices: Bandages, thermometers, and more.
- Personal Care Products: Skin care, birth control, and sexual wellness products.
- Baby Products: A range of baby care products.
111, Inc. also manages an online marketplace enabling third-party sellers to reach pharmacies. The company’s online loan application services support clients of 1 Drug Mall. 111, Inc. derives a majority of its revenue from the B2B segment.
Recent achievements include:
- Earnings Call Announcements: The company recently announced its Q3 2023 financial results showing net revenue growth of 9.5% year-over-year despite challenges in the macro-economy and retail pharmacy business.
- Digital Innovations: The 111 technology team secured three patents and won several prestigious awards in 2023 for their contributions to digital healthcare.
- Strategic Partnerships: 111, Inc. entered into a strategic direct supply partnership with Beijing Scrianen Pharmaceutical Co., Ltd., enhancing their collaboration to increase drug accessibility.
The company’s financial condition shows a strong trajectory with significant investments in digitalization and operational efficiency, ensuring sustainability and growth. The robust relationships with over 500 pharmaceutical partners and operational optimization for 450,000 retail pharmacies demonstrate their market leadership.
For more information on 111, please visit: http://ir.111.com.cn/.
111, Inc. (NASDAQ: YI) has formed a Special Committee comprising three independent directors to evaluate a preliminary non-binding proposal dated September 9, 2022, and potential strategic alternatives. The committee has engaged Houlihan Lokey China Limited as an independent financial advisor and Kirkland & Ellis as U.S. legal counsel. The Board advises shareholders that no decisions regarding the Proposal or any alternatives have yet been made, and no assurance is provided for any definitive agreements. The company continues to focus on connecting patients with healthcare services through its innovative platforms.
111 Inc. (NASDAQ: YI), a tech-enabled healthcare platform in China, announced that its Board has received an unsolicited preliminary non-binding proposal from Co-Founders Dr. Gang Yu and Mr. Junling Liu, along with Shanghai Guosheng Capital, to acquire all outstanding Class A shares at US$1.83 per share or US$3.66 per ADS. The proposal intends to fund the acquisition through equity capital, including cash contributions from the Sponsor. The Board has yet to evaluate the proposal, emphasizing no assurance of a definitive offer or agreement will occur.
111, Inc. (NASDAQ: YI) reported its unaudited financial results for Q2 2022, showcasing net revenues of RMB3.04 billion (US$453.4 million), up 0.4% YOY. Gross segment profit surged by 42.6%, with the B2B segment profit rising 55.1%. Operating expenses decreased to RMB271.7 million (US$40.6 million), down from RMB323.4 million last year, marking an improvement in operational efficiency. Despite challenges from COVID-19 lockdowns in Shanghai, non-GAAP loss from operations narrowed to RMB52.8 million (US$7.9 million), or 1.7% of net revenues, indicating progress towards profitability.
111, Inc. (NASDAQ: YI) will report its Q2 2022 unaudited financial results before U.S. markets open on August 25, 2022. An earnings conference call is scheduled for 7:30 AM U.S. Eastern Time on the same day. Participants must register online to receive dial-in details. 111, Inc. is a tech-enabled healthcare platform in China, connecting patients with pharmaceutical products and healthcare services through its online pharmacy and digital health services.
111, Inc. (NASDAQ: YI) reported first quarter 2022 financial results, achieving net revenues of RMB2.98 billion (US$470.5 million), a 14.9% year-over-year increase. Gross segment profit surged by 66.3%, with the B2B segment profit rising by 90.7%. Total operating expenses declined as a percentage of revenues to 9.9%. Non-GAAP loss from operations decreased to RMB72.4 million (US$11.4 million), or 2.4% of revenues. The company noted an increase in pharmaceutical partnerships to 550, reflecting strong market growth despite pandemic challenges.
111, Inc. (NASDAQ: YI) announced it will release its unaudited financial results for Q1 2022 on June 16, 2022, before U.S. market opens. The company's management will hold an earnings conference call at 7:30 AM ET on the same day, with registration required for participation. 111, Inc. operates a digital healthcare platform in China, connecting patients to medicine and healthcare services through its online pharmacy and internet hospital. The company offers various healthcare services, enhancing accessibility and efficiency for consumers.
On May 4, 2022, 111 Inc. (NASDAQ: YI) was provisionally listed as a "Commission-Identified Issuer" by the SEC under the Holding Foreign Companies Accountable Act. This follows the filing of its annual report on Form 20-F for the year ended December 31, 2021. The SEC's identification indicates that the Company used an auditor whose working papers are not fully inspectable by the PCAOB. If this is not addressed, trading of its securities may be prohibited on U.S. exchanges after three years. 111 Inc. is committed to maintaining compliance and protecting shareholder interests.
On April 13, 2022, 111, Inc. (NASDAQ: YI) announced its establishment of an 'Anti-Epidemic Command' to aid in Shanghai's COVID-19 response. The company has implemented various services including antigen test supplies, chronic disease medication registration, and online consultations. Following an initial shipment of essential items on April 7, 111 has enhanced its logistics for fast delivery. The online platform, 1 Pharmacy, offers over 100,000 drugs, while 1 Clinic provides virtual consultations. Dr. Yu Gang emphasized the company's commitment to support Shanghai's healthcare needs during the pandemic.
111, Inc. (YI) reported its Q4 and full-year 2021 financial results, highlighting a 30.9% YoY increase in net revenues to RMB 3.46 billion (US$ 543.1 million) for Q4, and a 51.5% YoY increase to RMB 12.4 billion (US$ 1.95 billion) for the fiscal year. Gross segment profit surged 98% YoY in Q4, with a 70% increase annually. Notably, the company expanded its partnerships to 515 pharmaceutical companies. Despite a non-GAAP loss from operations of RMB 76.9 million (US$ 12.1 million), the loss margin improved significantly from 4.2% to 2.2% YoY.
On March 14, 2022, 111, Inc. (NASDAQ: YI) entered a strategic partnership with Shenzhen BGI Co., Ltd. to distribute SARS-CoV-2 Virus Antigen Detection Kits through its online pharmacy, 1 Pharmacy. This collaboration will make 1 Pharmacy the first online platform in China to offer these kits, starting pre-sales this week. This initiative aims to enhance epidemic prevention efforts across China by providing better access to testing resources directly to consumers via a digital platform.
FAQ
What is the current stock price of 111 American Depositary Shares (YI)?
What is the market cap of 111 American Depositary Shares (YI)?
What is 111, Inc.?
What products does 111, Inc. offer?
How does 111, Inc. generate revenue?
What recent achievements has 111, Inc. made?
Who are 111, Inc.’s strategic partners?
What are the key services provided by 111, Inc.?
What is the financial condition of 111, Inc.?
How does 111, Inc. leverage digital technology?
What is the significance of the partnership with Scrianen?
Where can I find more information about 111, Inc.?
